<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37148453</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2576</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Inflammation</Title><ISOAbbreviation>Inflammation</ISOAbbreviation></Journal><ArticleTitle>Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>1458</StartPage><EndPage>1470</EndPage><MedlinePgn>1458-1470</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10753-023-01821-6</ELocationID><Abstract><AbstractText>To study the relationship of serum PCSK9 and disease activity and major adverse cardiovascular events (MACEs) in systemic lupus erythematosus (SLE). Consecutive patients who fulfilled &#x2265; 4 ACR criteria for SLE and consented for a biomarker study in 2009-2013 were included. Stored serum samples were assayed for PCSK9. PCSK9 levels were correlated with SLE disease activity scores. Patients were divided into two groups according to the median PCSK9 level and new MACEs over time were evaluated. The effect of PCSK9 level on MACEs and mortality was studied by Cox regression, adjusted for confounders. A total of&#xa0;539 SLE patients were studied (93% women, age 41.9 &#xb1; 14.0 years). The median PCSK9 level at baseline was 220 ng/ml. Patients with higher PCSK9 (&#x2265; 220 ng/ml; n = 269) had significantly higher SLE disease activity index (SLEDAI) than those with lower PCSK9 (&lt; 220 ng/ml; n = 270). PCSK9 levels were significantly higher in patients with active renal than active non-renal SLE, which in turn were significantly higher than those with inactive SLE or healthy controls. PCSK9 level correlated with SLEDAI in the overall population (&#x3c1; = 0.30; p &lt; 0.001). Over 91.3 &#xb1; 18.6 months, 29 patients developed 31 MACEs and 40 patients succumbed (25% for vascular events). The cumulative incidence of MACEs at 5 years was 4.8% in the higher PCSK9 and 1.1% in the lower PCSK9 group (HR2.51[1.11-5.70]; p = 0.03). Cox regression revealed higher PCSK9 was significantly associated with MACEs (HR1.003[1.000-1.005] per ng/ml; p = 0.02) independent of age, sex, renal function, baseline disease activity score, traditional atherosclerotic risk factors, antiphospholipid antibody and the use of aspirin/warfarin, statins and immunosuppressive drugs. PCSK9 level was also independently associated with all-cause (HR1.002[1.000-1.004] per ng/ml; p = 0.03) and vascular mortality (HR1.004[1.000-1.007]; p = 0.04). We concluded that serum PCSK9 level correlates with SLE&#xa0;disease activity. Higher serum PCSK9 levels are associated with increased risk of cardiovascular events and mortality in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chi Chiu</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0003-3696-1228</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong SAR, China. ccmok2005@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Ling Yin</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Kar Li</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Sau Mei</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>To</LastName><ForeName>Chi Hung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Pok Oi Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Inflammation</MedlineTA><NlmUniqueID>7600105</NlmUniqueID><ISSNLinking>0360-3997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D013381">Subtilisins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071449" MajorTopicYN="N">Proprotein Convertase 9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013381" MajorTopicYN="N">Subtilisins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PCSK9</Keyword><Keyword MajorTopicYN="N">cardiovascular</Keyword><Keyword MajorTopicYN="N">disease activity.</Keyword><Keyword MajorTopicYN="N">lupus</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>14</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37148453</ArticleId><ArticleId IdType="doi">10.1007/s10753-023-01821-6</ArticleId><ArticleId IdType="pii">10.1007/s10753-023-01821-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown, M.S., R.G. Anderson, and J.L. Goldstein. 1983. Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell 32: 663&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">6299572</ArticleId><ArticleId IdType="doi">10.1016/0092-8674(83)90052-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Handelsman, Y., and N.E. Lepor. 2018. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association 7: e008953.</Citation><ArticleIdList><ArticleId IdType="pubmed">29934421</ArticleId><ArticleId IdType="pmc">6064883</ArticleId><ArticleId IdType="doi">10.1161/JAHA.118.008953</ArticleId></ArticleIdList></Reference><Reference><Citation>Abifadel, M., S. Elbitar, P. El Khoury, Y. Ghaleb, M. Ch&#xe9;maly, M.L. Moussalli, et al. 2014. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Current Atherosclerosis Reports 16: 439.</Citation><ArticleIdList><ArticleId IdType="pubmed">25052769</ArticleId><ArticleId IdType="doi">10.1007/s11883-014-0439-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotowski, I.K., A. Pertsemlidis, A. Luke, R.S. Cooper, G.L. Vega, J.C. Cohen, et al. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. American Journal of Human Genetics 78: 410&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">16465619</ArticleId><ArticleId IdType="pmc">1380285</ArticleId><ArticleId IdType="doi">10.1086/500615</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsted, A., B.G. Nordestgaard, M. Benn, A. Tybj&#xe6;rg-Hansen, and P.R. Kamstrup. 2016. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. Journal of Clinical Endocrinology and Metabolism 101: 3281&#x2013;3287.</Citation><ArticleIdList><ArticleId IdType="pubmed">27218270</ArticleId><ArticleId IdType="doi">10.1210/jc.2016-1206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, Z., Y. Tuakli-Wosornu, T.A. Lagace, L. Kinch, N.V. Grishin, J.D. Horton, et al. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. American Journal of Human Genetics 79: 514&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909389</ArticleId><ArticleId IdType="pmc">1559532</ArticleId><ArticleId IdType="doi">10.1086/507488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscica, M., N. Ferri, F. Fogacci, M. Rosticci, M. Botta, S. Marchiano, et al. 2017. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association 6: e005764.</Citation><ArticleIdList><ArticleId IdType="pubmed">28468788</ArticleId><ArticleId IdType="pmc">5524108</ArticleId><ArticleId IdType="doi">10.1161/JAHA.117.005764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y., W. Chen, M. Lu, and Y. Wang. 2021. Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis. Front Cardiovasc Med 8: 617249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33738300</ArticleId><ArticleId IdType="pmc">7960648</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2021.617249</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th, &#x160;, J. Feda&#x10d;ko, T. Pek&#xe1;rov&#xe1;, Z. Hertelyov&#xe1;, M. Katz, A. Mughees, et al. 2017. Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients. Cardiol Ther 6: 281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">28623549</ArticleId><ArticleId IdType="pmc">5688969</ArticleId><ArticleId IdType="doi">10.1007/s40119-017-0092-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, W., J. Liu, W. Wang, M. Wang, Y. Qi, F. Zhao, et al. 2016. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. International Journal of Cardiology 215: 293&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">27128549</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2016.04.103</ArticleId></ArticleIdList></Reference><Reference><Citation>Nose, D., Y. Shiga, Y. Ueda, Y. Idemoto, K. Tashiro, Y. Suematsu, et al. 2019. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart and Vessels 34: 19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">29974199</ArticleId><ArticleId IdType="doi">10.1007/s00380-018-1218-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, J., Y.N. Yang, Z. Cui, S.Y. Feng, J. Ma, C.P. Li, et al. 2021. Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction. Lipids in Health and Disease 20: 56.</Citation><ArticleIdList><ArticleId IdType="pubmed">34044829</ArticleId><ArticleId IdType="pmc">8161665</ArticleId><ArticleId IdType="doi">10.1186/s12944-021-01478-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, S., Y. Zhang, R.X. Xu, Y.L. Guo, C.G. Zhu, N.Q. Wu, et al. 2015. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Annals of Medicine 47: 386&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">26153823</ArticleId><ArticleId IdType="doi">10.3109/07853890.2015.1042908</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, J., M.M. Liu, J.L. Jin, Y.X. Cao, Y.L. Guo, N.Q. Wu, et al. 2020. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovascular Diabetology 19: 167.</Citation><ArticleIdList><ArticleId IdType="pubmed">33023603</ArticleId><ArticleId IdType="pmc">7541318</ArticleId><ArticleId IdType="doi">10.1186/s12933-020-01142-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberale, L., F. Carbone, M. Bertolotto, A. Bonaventura, A. Vecchi&#xe9;, F. Mach, et al. 2018. Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. International Journal of Cardiology 263: 138&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">29754909</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2018.03.081</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao, T.H., I.C. Chen, Y.H. Li, P.T. Lee, and S.Y. Tseng. 2016. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells. Journal of the American Heart Association 5: e003497.</Citation><ArticleIdList><ArticleId IdType="pubmed">27207972</ArticleId><ArticleId IdType="pmc">4889209</ArticleId><ArticleId IdType="doi">10.1161/JAHA.116.003497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheirkhah, A., C. Lamina, B. Rantner, B. Kollerits, M. Stadler, J. Pohlhammer, et al. 2021. Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study. Atherosclerosis 316: 41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">33302043</ArticleId><ArticleId IdType="doi">10.1016/j.atherosclerosis.2020.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministrini, S., and F. Carbone. 2022. PCSK9 and Inflammation: Their Role in Autoimmune Diseases, with a Focus on Rheumatoid Arthritis and Systemic Lupus Erythematosus. Current Medicinal Chemistry 29: 970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">34375179</ArticleId><ArticleId IdType="doi">10.2174/0929867328666210810150940</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd, J.H., C.D. Fjell, J.A. Russell, D. Sirounis, M.S. Cirstea, and K.R. Walley. 2016. Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis. Journal of Innate Immunity 8: 211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756586</ArticleId><ArticleId IdType="pmc">6738828</ArticleId><ArticleId IdType="doi">10.1159/000442976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianconi, V., E. Schiaroli, M. Pirro, S. Cardaci, C. Busti, M.R. Mannarino, et al. 2020. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters. HIV Medicine 21: 512&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">32496664</ArticleId><ArticleId IdType="doi">10.1111/hiv.12884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C.C. 2017. Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. Expert Review of Clinical Immunology 13: 677&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">28443384</ArticleId><ArticleId IdType="doi">10.1080/1744666X.2017.1323635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C.C. 2006. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scandinavian Journal of Rheumatology 35: 85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16641040</ArticleId><ArticleId IdType="doi">10.1080/03009740600601526</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce, I.N., M.B. Urowitz, D.D. Gladman, D. Iba&#xf1;ez, and G. Steiner. 2003. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis and Rheumatism 48: 3159&#x2013;3167.</Citation><ArticleIdList><ArticleId IdType="pubmed">14613278</ArticleId><ArticleId IdType="doi">10.1002/art.11296</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz, M.B., A.A. Bookman, B.E. Koehler, D.A. Gordon, H.A. Smythe, and M.A. Ogryzlo. 1976. The bimodal mortality pattern of systemic lupus erythematosus. American Journal of Medicine 60: 221&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">1251849</ArticleId><ArticleId IdType="doi">10.1016/0002-9343(76)90431-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, C., T. Luo, and L. Lin. 2018. Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus. Ann Transl Med 6: 452.</Citation><ArticleIdList><ArticleId IdType="pubmed">30603640</ArticleId><ArticleId IdType="pmc">6312819</ArticleId><ArticleId IdType="doi">10.21037/atm.2018.11.04</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-P&#xe9;rez, H., J.C. Quevedo-Abeledo, B. Tejera-Segura, L. de Armas-Rillo, I. R&#xfa;a-Figueroa, M.A. Gonz&#xe1;lez-Gay, et al. 2020. Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Therapeutic Advances in Musculoskeletal Disease 12: 1759720X20975904.</Citation><ArticleIdList><ArticleId IdType="pubmed">33294038</ArticleId><ArticleId IdType="pmc">7705780</ArticleId><ArticleId IdType="doi">10.1177/1759720X20975904</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, A., M. Rahman, I. Hafstr&#xf6;m, S. Ajeganova, and J. Frosteg&#xe5;rd. 2020. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. Lupus 29: 825&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">32479241</ArticleId><ArticleId IdType="doi">10.1177/0961203320926253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 40: 1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobi&#xe1;&#x161;ov&#xe1;, M. 2004. Atherogenic Index of Plasma [Log(Triglycerides/HDL-Cholesterol)]: Theoretical and Practical Implications. Clinical Chemistry 50: 1113&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229146</ArticleId><ArticleId IdType="doi">10.1373/clinchem.2004.033175</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobi&#xe1;sov&#xe1;, M., and J. Frohlich. 2001. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clinical Biochemistry 34: 583&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738396</ArticleId><ArticleId IdType="doi">10.1016/S0009-9120(01)00263-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo, M.S., W.L. Cheah, S. Lwin, T. Moe Nwe, T.T. Win, and M. Aung. 2018. Understanding the Relationship between Atherogenic Index of Plasma and Cardiovascular Disease Risk Factors among Staff of an University in Malaysia. Journal of Nutrition and Metabolism 2018: e7027624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7027624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobi&#xe1;sov&#xe1;, M. 2006. AIP&#x2013;atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitrni Lekarstvi 52: 64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16526201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, T.T., Y. Gao, Y.Y. Zheng, Y.T. Ma, and X. Xie. 2018. Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids in Health and Disease 17: 197.</Citation><ArticleIdList><ArticleId IdType="pubmed">30134981</ArticleId><ArticleId IdType="pmc">6106932</ArticleId><ArticleId IdType="doi">10.1186/s12944-018-0828-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey, A.S., J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine 130: 461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075613</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-130-6-199903160-00002</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri, M., M.Y. Kim, K.C. Kalunian, J. Grossman, B.H. Hahn, L.R. Sammaritano, et al. 2005. Combined oral contraceptives in women with systemic lupus erythematosus. The New England journal of medicine 353: 2550&#x2013;2558.</Citation><ArticleIdList><ArticleId IdType="pubmed">16354891</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman, D., E. Ginzler, C. Goldsmith, P. Fortin, M. Liang, M. Urowitz, et al. 1996. The development and initial validation of the systemic lupus. Arthritis and Rheumatism 39: 363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">8607884</ArticleId><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia, N., J. Blacher, F.S. de Edelenyi, P. Faure, C. Julia, S. Hercberg, et al. 2013. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis 228: 478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">23582589</ArticleId><ArticleId IdType="doi">10.1016/j.atherosclerosis.2013.03.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, T.J., P. Gona, M.G. Larson, G.H. Tofler, D. Levy, C. Newton-Cheh, et al. 2006. Multiple biomarkers for the prediction of first major cardiovascular events and death. New England Journal of Medicine 355: 2631&#x2013;2639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182988</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa055373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zethelius, B., L. Berglund, J. Sundstr&#xf6;m, E. Ingelsson, S. Basu, A. Larsson, et al. 2008. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. New England Journal of Medicine 358: 2107&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">18480203</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa0707064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis, A., M. Kostopoulou, K. Cheema, H.J. Anders, M. Aringer, I. Bajema, et al. 2020. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 79: 713&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">32220834</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C.C., L. Hamijoyo, N. Kasitanon, D.Y. Chen, S. Chen, K. Yamaoka, et al. 2021. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. The Lancet Rheumatology 3: e517&#x2013;e531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00009-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaharir, S.S., H. Hussein, S. Rajalingham, M.S. Mohamed Said, A.H. Abdul Gafor, R. Mohd, et al. 2016. Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts Worldwide. PLoS ONE 11: e0166270.</Citation><ArticleIdList><ArticleId IdType="pubmed">27846298</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0166270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok, C.C., S.M. Tse, K.L. Chan, and L.Y. Ho. 2018. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 27: 722&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">29087260</ArticleId><ArticleId IdType="doi">10.1177/0961203317739129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, Z.H., L.J. Zhang, W.X. Liu, Y.S. Lei, G.L. Xing, J.J. Zhang, et al. 2012. Predictors of survival in Chinese patients with lupus nephritis. Lupus 21: 1049&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513365</ArticleId><ArticleId IdType="doi">10.1177/0961203312445230</ArticleId></ArticleIdList></Reference><Reference><Citation>Frosteg&#xe5;rd, J., S. Ahmed, I. Hafstr&#xf6;m, S. Ajeganova, and M. Rahman. 2021. Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-&#x3b1;: potential underlying mechanisms. Arthritis Research &amp; Therapy 23: 32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02386-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci, C., M. Ruscica, M. Camera, L. Rossetti, C. Macchi, A. Colciago, et al. 2018. PCSK9 induces a pro-inflammatory response in macrophages. Science and Reports 8: 2267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20425-x</ArticleId></ArticleIdList></Reference><Reference><Citation>de Armas-Rillo, L., J.C. Quevedo-Abeledo, A. de Vera-Gonz&#xe1;lez, A. Gonz&#xe1;lez-Delgado, J.A. Garc&#xed;a-Dopico, A. Jimenez-Sosa, et al. 2021. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. Rheumatology (Oxford) 60: 2296&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pubmed">33295631</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa590</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, Z., L. Hu, J. Zhang, W. Yang, X. Liu, D. Jia, et al. 2021. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation 143: 45&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">32988222</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.046290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>